The phase III VIVID-1 study demonstrated exceptional potential, meeting all primary and secondary benchmarks over a 52-week treatment span.
Eli Lilly has unveiled promising results for its experimental drug, mirikizumab (Omvoh), in the treatment of moderate-to-severe Crohn’s disease (CD)
Impressively, 51.4% of CD patients achieved clinical remission on the drug, a substantial surge compared to the 19.6% on a placebo. While Eli Lilly’s mirikizumab did not surpass Johnson & Johnson’s Stelara in terms of endoscopic response, with the latter showing slightly higher results, Eli Lilly remains optimistic. Encouraged by the overall positive outcome, the company intends to pursue regulatory approval from the FDA and international agencies for Eli Lilly’s mirikizumab in CD indication in the coming year.
However, Eli Lilly’s mirikizumab faces robust competition from AbbVie’s Skyrizi, a similar drug that has already gained label expansion for CD indication in the United States and Europe.
AbbVie is actively seeking further applications for Skyrizi, currently pursuing label expansion from the FDA and European Medicines Agency (EMA) for ulcerative colitis (UC) indications
The drug has already received approval for treating active psoriatic arthritis and moderate-to-severe psoriasis. These strides exemplify the unwavering commitment of pharmaceutical giants like Eli Lilly and AbbVie in broadening their spectrum of treatments for inflammatory diseases such as CD and UC, heralding newfound hope for patients grappling with these conditions.
READ ALSO: Rising Epidemic: Debilitating Chronic Pain Afflicts Millions In The U.S.